Company: INTS
Filing Date: 2025-03-28
Form Type: DRS
Source: 0001628279-25-000170
Chunk: 56

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-28
Form: DRS
Chunk 56
---
 agreed, subject to specified exceptions, not to sell or transfer any shares of Common Stock or securities convertible

<div align='center'>35

Confidential Treatment Requested by Intensity Therapeutics, Inc.</div>

#### Pursuant to 17 C.F.R. Section 200.83
into, or exchangeable or exercisable for, Common Stock during a period ending days after the completion of this offering, without first obtaining the written consent of the Placement Agents. Specifically, these individuals agreed, in part, subject to certain exceptions, not to:

• sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open “put equivalent position” within the meaning of Rule 16al(h) under the Exchange Act;

• enter into any swap or other agreement, arrangement, hedge or transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic

• consequences of ownership of our securities, whether any such transaction is to be settled by delivery of shares of our Common Stock, in cash or otherwise;

• publicly announce the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge; or

• other arrangement relating to any of our securities.

Notwithstanding these limitations, these shares of Common Stock may be transferred under limited circumstances, including, without limitation, by gift, will or intestate succession.

In addition, we have agreed that (i) we will not conduct any issuances of our shares of Common Stock for a period of days following closing of this offering, and that (ii) we will not enter into a variable rate transaction for a period of months following the closing of this offering, with the exception of an at-the-market transaction, under which we will not issue any securities for a period of days following the closing of this offering.

#### Regulation M
Each Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, each Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the